This is of immediate concern as few preclinicalstudies have tested VEGF pathway inhibitors in clinically appropriate models of late-stagemetastatic disease (Guerin et al, 2013), and even fewer still have modeled treatments in the perioperative setting withspontaneous metastatic disease similar to patients. The gene discussed is VEGFA; the disease is metastatic neoplasm.